ICER Updates Leqembi Price Range Recommendations

The Institute for Clinical and Economic Review (ICER) released an update to its recently released value assessment of the Leqembi (lecanemab). ICER changed its price recommendation for Eisei’s new Alzheimer’s treatment to a range of $8,900 to $21,500 per year. This price is higher than its initial assessment but still lower than the drug’s list price.

According to Angus Liu, “The new recommended price means Eisai should take 19% to 66% off of Leqembi’s current list price of $26,500, ICER contends. Still, the upper end of ICER’s new range marked a $900 increase from the group’s original report, which was published in December. Before finalizing the report, ICER will hold a virtual public meeting March 17 to review the analysis.”

To read more, click here.

(Source: Fierce Pharma, March 1^st, 2023)